and Results: Transthoracic cardioversion was performed 85 * 187 days (range 7 minutes to 8 years) after the onset of atrial fibrillation in 315 patients who had a mean age of 6lil3 year?,. IRAF was defined as a recurrence of AF within 60 seconds after restoration of sinus rhythm.
Background:
Paroxysmal atrial fibrillation (PAF) IS one of the most c~mmcm causes of hospital admissron. However, until now, no standard antiarrhythmic therapy has been accepted for pharmacological cardioversron of PAF. Amiodarone seems to be a promising candidate, but only a few small, randomwad trials are available and the results are inconsitent.
Aim of the study: To assess efficacy of intravenous amiodarone in cardioversion of PAF.
Methods: 160 patients with PAF lasting less than 24 hours were randomly assigned (2:1) to amiodarone group (n=l06) receiving 5 mg/kg as a 30 min. iv infusion, followed by infusion of 10 mglkg during 20 hours and to the control grup (n=54). Both groups received 1000 ml of 10% glucose with 20 IU of rapid action insulin, 60 mEq of potassium chloride and 8 g of magnesium sulphate (GIKM) which is electrolyte supplementation routinely used in our department rn patients with PAF. Patients requiring emergency DC cardioversion were excluded.
Results: Up to 8 hours after initiation of treatment 53 (50%) patients in amiodarone group and 14 (26%) patients in control group were converted to sinus rhythm (~~0.05). Twenty hours after initiation of the therapy sinus rhythm was restored in 88 (83%) patients in the amiodarone group and in 24 (44%) patients in the control group (p<o.oool).
Conclusion:
This study, which is one of the largest ever done on this subject, showed that amiodarone is effective in termination of PAF lasting less than 24 hours. It may be particularly useful in patients with left ventricular dysfunction, in whom class I antiarrhythmic agents are contraindicated.
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Study: A Randomized Study Comparing Outpatient Dalteparin Administration to Inpatient Heparin for the Initiation of Anticoagulation in Atrial Fibrillation
Francois Philippon, Gilles E. CSHara, Jean Champagne, Lyne Charbonneau, Helene
Villeneuve, Louis Blier, Franck Mokn, Marcel Gilbert, Quebec Heart Institute, Sainte-Fey.
PQ, Canada
Atrial fibrillation (AF) patrents who need to be anticoagulated are often admitted to the hospital to receive IV heparin until the therapeutic INR has been reached. Some pts are sent home on warfarin alone with a potential risk for stroke. We conducted a prospective randomized trial compahng ah outpatient strategy using dalteparin (200 I.U./Kg, maximum 18 000 I.U.) + warfarin (Da) to standard IV heparin + warfarin (He). A total of 192 pts were randomized in a B(Da):l(He) ratio and 186 (Da:l42. He:44) completed the study (56 women, 130 men). The mean age was 70 * IO yrs and 44 % had a cardiovascular history and 50% had hypertension. 47% presented with paroxysmal AF, 50% with persistent AF and 3% were in chronic AF. The mean EF was 59 f 11% and mean left atrial size 42 r 7 mm. Sinus rhythm was achieved spontaneously in 64 pts, 18 received ah antiarrhythmic agent and 18 were electrically cardioverted. To achieve proper anticoagulation, the He group required a mean of 6.4 + 2.0 days of in-hospital IV heparin and the Da group 6.4 21.6 s/c injections. After 21 days, all pts were seen in clinic, 57 were rn AF, 5 in atrial flutter, 5 were paced and 119 were in sinus rhythm. Cost-effective and quality of life analysis were performed. No major complications or death were observed during the study period. Two thromboembotic complications were seen: one in the Da group with a pt presenting initially with a TIA the day before randomization (later recognized) and one pt in the He group where on day 21 a minor neurological deficit was noticed. Three pts in the He group presented with minor hemorrhagic complications (I ecchymosis and 2 slight Hb drops). In the Da group, 12 pts had small ecchymosis at the injection site, 5 had minor epistaxis (one requiring medical anentton without transfusion or hospital admission in a pt with concomitant clopidogrel use), 4 had hematomas at the injection site (one required medical attention wrthout transfusion while receiving concomitant celecoxib).
Conclusion:
The use of dalteparin for the initiation of anticoagulation in pts with atrial fibrillation is a safe alternative to the conventional approach using IV heparin. It offers a cost-effective outpatient strategy that can alleviate the need for hospitalization.
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Effect of Atrial Fibrillation Duration on Probability of Immediate Recurrence After Transthoracic Cardioversion
Hakan Oral Mehmet Ozaydin. Christian Sticherling, Hiroshi Tada, Christoph Scharf, -I Aman Chugh, Frank Pelosi, Jr., Bradley P. Knight, Fred Morady, Unwersity of Michigan, Ann Arbor, Ml Background:
An immediate recurrence of atria1 fibrillation (IRAF) appears to be mcwe crxnrrwn after early restoratron of sinus rhythm with ah implantable atrial defibrillator than after elective transthoracic cardiovenion, suggesting that the probability of IRAF may be related to the duration of AF. (p=O.21, explorative). Incidence of the primary endpoint was 3.2% (7/216) for enoxaparin vs 5.6% (12/212) for UFH/OAC (p=O.O17. confirmatory for equivalence with delta=2%).
Conclusions:
Enoxaparin shows non-inferior efficacy and safety to UFH/OAC in CV of AF, and may be preferred due to its reproducibility of anticoagulative effect and mare convenient S.C. administration. Only left ventricular ejection fraction (LVEF) was related to hsCRP in multivariate analysis, however LVEF was not statistically different between both groups. The odds ratio of developing recurrence was 9 with every 0.5 unit increase over 0.554 (pvalue<0.001).
1015-17
Brain Natriuretic Peptide Levels Predict Successful Cardioversion and Rhythm Maintenance in Patients With Chronic Atrial Fibrillation
RRR=25%; p=O.57) in DDD-RV, 44% (4/9; RRR=BO%: p&1.13) in DDD-LV and 22% (2/9; RRR=75%; p=O.O18) in DDD-BiV. Conclusion: BiVP improves repolarization properties as measured by a reduction of TWA, thus contnbuting to the reduction of ventricular arrhythmias through this novel mechanism. Methods: Patients (n=13) with permanent BiVP were studled. TWA were measured by spectral method using Heartwave system (Cambridge Heart) at rapid atrial (AAI) and various ventricular (DDD) pacing modes. TWA were interpreted by standard protocol.
T Wave Alternans 8
Results: Four patients were excluded due to AV block at cl05 bpm. on 9/l l/01. In our cohort of 200 patients there was a 2.3-fold increase in risk in the 30 days after 9/l 1 versus the 30 days before. We sought to evaluate the ICD discharge rate in this population over an 8 month observation period and to detenine when the increased rate of discharges returned to pre 9/l 1 levels. Methods:
To determine the pattern of daily arrhythmic events from 5/l l/O1 to l/10/02, triggering ICD discharges over the 8 month time period, a logistic model and a generalized estimating equation approach to account for within subject correlation were employed.
Results:
The incidence of ICD activation for ventricular tachvarrhvthmias for Mav , , 
